Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun 01; 17(11):3716-26.

View in: PubMed

authors with profiles

Pablo Vivas

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support